Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2020

View Archived Issues

Sotira successfully completes preclinical testing of KEPTIDE COVID

Phase II experience with transmission blocking vaccine Pfs230D1M-EPA/AS01

Two first-in-human adjuvanted malaria vaccines presented

ASGR1-TLR8: an immunoTAC for the potential treatment of chronic HBV

Genfleet Therapeutics describes new RIPK1 inhibitors

TYK Medicines divulges protein kinase inhibitors

Idorsia Pharmaceuticals synthesizes new PDK1 inhibitors

Chaser Therapeutics identifies new USP28 and USP25 inhibitors

Constellation Pharmaceuticals initiates phase III MANIFEST-2 study of CPI-0610

Initial successful data presented for RLF-100 in critical COVID-19 with severe comorbidity

Abmax Biopharmaceuticals TNF-alpha-targeting antibodies

Ionis licenses second NASH candidate to AstraZeneca

Merck initiates phase II study of MK-3655 in precirrhotic NASH

Aleta presents novel CAR T-engager proteins targeting metastatic and primary CNS malignancies

Promising phase II data for MDNA-55 delivered by CED in patients with recurrent GBM

New mutations don't appear to increase SARS-CoV-2 transmissibility

Novel model of SARS-CoV-2 infection in deer mice

Faron outlines expansion plans for Clevegen development

Golden Biotechnology reports phase IIa results with antroquinonol in relapsed AML

Phase IIb data presented for GMZ2 malaria vaccine in children

Evrenzo approved in Japan for CKD anemia in adults not on dialysis

Haoma completes first-in-human study of NaQuinate for osteoporosis

E.U. approval for Symkevi with Kalydeco for children with cystic fibrosis aged 6-11 years

Petrovax partners with Intellogic to study Longidaze for pulmonary fibrosis in COVID-19 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...